Document is current
Any future updates will be listed below
-
Authors
Nesbitt, Natasha M. https://orcid.org/0000-0001-5549-0383
Araldi, Gian Luca
Pennacchia, Lisa https://orcid.org/0000-0002-4248-0482
Marchenko, Natalia
Assar, Zahra https://orcid.org/0000-0001-6008-6203
Muzzarelli, Kendall M. https://orcid.org/0000-0003-1488-0750
Thekke Veedu, Rahul Raghavan https://orcid.org/0000-0003-3553-980X
Medel-Lacruz, Brian https://orcid.org/0000-0003-2831-7731
Lee, Eunjeong
Eisenmesser, Elan Z.
Kreitler, Dale F. https://orcid.org/0000-0003-4758-7913
Bahou, Wadie F. https://orcid.org/0000-0001-6527-8503
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (HL150927, CA284999, GM139892, HL153144)
National Science Foundation (NSF2332239)
- License Information
-
More Information
Article History
Received: 16 July 2024
Accepted: 17 March 2025
First Online: 11 April 2025
Competing interests
: N.M.N. is the Chief Scientific Officer of Blood Cell Technologies, which is developing selective BLVRB redox inhibitors for therapeutic applications. W.F.B. is the Founder of Blood Cell Technologies. The remaining authors declare no competing interests.
